From: Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer
Variable N= 112 | Median ± SE | Number (%) |
---|---|---|
Age (years) | 50 ± 11 |  |
Tumor size (cm) | 5 ± 1.56 Mean, 3.93 |  |
Clinical T stage* | Â | Â |
   T2 |  | 22 (19.6) |
   T3 |  | 50 (44.6) |
   T4 |  | 40 (35.7) |
Clinical N stage* | Â | Â |
   N1 |  | 55 (49.1) |
   N2 |  | 56 (50) |
   N3 |  | 1 (0.9) |
Clinical stage* | Â | Â |
   IIB |  | 24 (21.4) |
   IIIA |  | 48 (42.9) |
   IIIB |  | 40 (35.7) |
Histological grade†|  |  |
   Low/moderate |  | 45 (40.2) |
   High |  | 67 (59.8) |
Estrogen receptors | Â | Â |
   Positive |  | 48 (42.9) |
   Negative |  | 64 (57.1) |
Progesterone receptors | Â | Â |
   Positive |  | 46 (41.1) |
   Negative |  | 66 (58.9) |
Treatment after CCRTh | Â | Â |
   Anthracycline |  | 54 (48.2) |
   Taxanes |  | 58 (51.8) |